At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 6 enrolled
Drug / intervention
AUT00201 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Crossover Study of the Effects of Single Doses of AUT00201 in Patients With Myoclonus Epilepsy and Ataxia Due to Potassium (K+) Channel Mutation (MEAK)
In Brief
A Phase 1 clinical trial evaluating AUT00201 and Placebo for Myoclonus Epilepsies, Progressive. Completed, enrolled 6 participants across 1 site.
Detailed Summary
A randomized, double-blind, placebo-controlled, crossover study to assess the safety, tolerability, and pharmacokinetics of single doses of AUT00201 at 100 mg or matching placebo in patients with myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyoclonus Epilepsies, Progressive
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
Enrollment StartMay 2023
First PostedMay 2023
Primary CompletionMay 2024
TodayJul 2026
First PostedMay 24, 2023
Enrollment StartMay 12, 2023
Primary CompletionMay 1, 2024
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 3.1 years ago
Interventions
AUT00201drug
Single oral dose
Placebodrug
Single oral dose